Listed by the USPTO as HIRAKIS, SOPHIA P
Tech Center 1600 • Art Units: 1623
This examiner grants 57% of resolved cases
HIRAKIS, SOPHIA P has resolved 61 cases in tech center 1600 and art unit 1623. The allowance rate is 57.4%, and interview lift is 69.8%. The positive interview measure is substantial in the recorded docket, indicating that an interview may be an important tool for addressing examination concerns.
The median time to allowance is 1356 days. Because the resolved-case volume is limited, applicants should use the figures as directional guidance and continue to assess each application on its claims and record. The recurring companies are Genentech Inc., Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., and The Regents of the University of California. The recurring firms are Fox Rothschild LLP, AMSTER, ROTHSTEIN & EBENSTEIN LLP, and ARENTFOX SCHIFF LLP - New York.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17643623 | QUINAZOLINYL COMPOUNDS AND METHODS OF USE | Non-Final OA | Genentech, Inc. |
| 18577179 | BROAD-SPECTRUM ANTIVIRAL DRUGS | Non-Final OA | FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. |
| 18026330 | LIGHT-CONTROLLED BIOORTHOGONAL TETRAZINE LIGATION | Non-Final OA | The Regents of the University Of California |
| 18859673 | NEXT GENERATION DIPROVOCIMS THAT ACTIVATE THE INNATE AND ADAPTIVE IMMUNE RESPONSE | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18396272 | COMPOUND, MANUFACTURING METHOD THEREFOR, ANTIMICROBIAL AGENT, AND MEDICINAL DRUG | Non-Final OA | National University Corporation Hokkaido University |
| 18559689 | Substituted Spiro Derivatives | Non-Final OA | Janssen Pharmaceutica NV |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.4% of resolved applications examined by Sophia P Hirakis were allowed (61 resolved cases), compared with 51.3% across Art Unit 1623 over the last five years.
This examiner's interview lift is +69.8 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sophia P Hirakis took 1,356 days on average from filing to allowance.
Sophia P Hirakis examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
